Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04389294 · ClinicalTrials.gov registry record · NA
HSS Covid-19 Antibody Serology Among Surgeons & Anesthesiologists
A NA study of COVID, sponsored by Hospital for Special Surgery, New York.
- Completed
- Registry status
- NA
- Development phase
- 143
- Enrollment target
- 1
- Study location
NCT04389294 is a NA study of COVID that has completed, run by Hospital for Special Surgery, New York. The registered enrollment target is 143 participants, below the 2,593-participant average among 14 other COVID trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04389294, a NA study of COVID, has completed, sponsored by Hospital for Special Surgery, New York.
- COMPLETED
- Registry status
- NA
- Development phase
- 143 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this study is to understand the infectious exposure of SARS-coronavirus 2 (SARS-CoV2) among surgeons and anesthesiologists and to correlate this status with self-reported indices of COVID-19 illness.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST SARS-CoV2 serum antibody testing
Study Locations (1)
New York
- Hospital for Special Surgery - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 143 participants |
| Start Date | 2020-05-05 |
| Est. Completion | 2020-09-04 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04389294
The ClinicalTrials.gov registry entry for NCT04389294 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 143 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,593-participant average among 14 other COVID trials with a reported enrollment target (94% lower). The listed sponsor is Hospital for Special Surgery, New York, which has 194 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with COVID appearing as the primary indexed condition, and to 1 intervention - of which SARS-CoV2 serum antibody testing is the first listed.
NCT04389294 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT04389294 about?
NCT04389294 is a clinical study titled "HSS Covid-19 Antibody Serology Among Surgeons & Anesthesiologists". The goal of this study is to understand the infectious exposure of SARS-coronavirus 2 (SARS-CoV2) among surgeons and anesthesiologists and to correlate this status with self-reported indices of COVID-19 illness.
What is the current status of trial NCT04389294?
This trial is currently completed. It is a NA study. The enrollment target is 143 participants. The study started on 2020-05-05. Estimated completion is 2020-09-04.
What conditions does trial NCT04389294 study?
This clinical trial studies the following conditions: COVID.
What interventions are being tested in trial NCT04389294?
The interventions under investigation include: SARS-CoV2 serum antibody testing (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT04389294?
This trial is sponsored by Hospital for Special Surgery, New York, which has 194 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04389294 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for COVID
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Clinical Validation of the Aptitude Medical Systems Metrix COVID-19 Test
RECRUITING · NA
-
Prospective Clinical Evaluation of the BioFire Emerging Coronavirus Panel for the Detection of COVID-19 and Other Coronaviruses
RECRUITING
-
Long-term Impact of Infection With Novel Coronavirus (COVID-19)
RECRUITING
-
Outpatient Treatment With Anti-Coronavirus Immunoglobulin
RECRUITING · Phase 3
-
A Study to Explore the Role of Gut Flora in COVID-19 Infection
RECRUITING
-
COVID-19 Biorepository
ACTIVE NOT RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.